Browsed by
Tag: Eton

Eton Pharmaceuticals initiates equity offering (NASDAQ:ETON)

Eton Pharmaceuticals initiates equity offering (NASDAQ:ETON)

Eton Pharmaceuticals (NASDAQ:ETON) -6% announces public offering to sell common shares.

Closing date is October 14, 2020.

Net proceeds will be used primarily for general corporate purposes, which may include research and development activities, capital expenditures, selling, general and administrative costs, and to meet working capital needs.

Price, volume and terms have yet to be determined.

Source: Press Release

Source Article Read the rest

Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock

Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

DEER PARK, Ill. , Oct. 13, 2020 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Wednesday, October 14, 2020.

Eton Pharmaceuticals intends to use the net proceeds from the offering primarily for general corporate purposes, which may include research and development activities, capital expenditures, selling, general and administrative costs, and to meet working capital needs.

National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ: NHLD), is acting as the sole book-running manager of the offering. The Liquid Venture Partners group at National Securities is responsible for sourcing and executing the offering.

The shares described above are being offered by Eton Pharmaceuticals pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from National Securities Corporation, Attn: Charles Wanyama, ECM -Syndicate, 200 Vesey

Read the rest
Eton Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Eton Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Eton Pharmaceuticals, Inc. ETON has been struggling lately, but the selling pressure may be coming to an end soon. That is because ETON recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.

What is a Hammer Chart Pattern?

A hammer chart pattern is a popular technical indicator that is used in candlestick charting. The hammer appears when a stock tumbles during the day, but then finds strength at some point in the session to close near or above its opening price. This forms a candlestick that resembles a hammer, and it can suggest that the market has found a low point in the stock, and that better days are ahead.

Other Factors

Plus, earnings estimates have been rising for this company, even despite the sluggish trading lately. In just the past 60 days alone 2 estimates have gone higher, compared to none lower, while the consensus estimate has also moved in the right direction.

Estimates have actually risen so much that the stock now has a Zacks Rank #2 (Buy) suggesting this relatively unloved stock could be due for a breakout soon. This will be especially true if ETON stock can build momentum from here and find a way to continue higher of off this encouraging trading development. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See

Read the rest
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application
for Orphan Drug Dehydrated Alcohol Injection

- Application Assigned a PDUFA Date of May 27, 2021

- Dehydrated Alcohol Injection Market Estimated to be Greater Than $100
Million Annually

- Application has Received Orphan Drug Designation for Methanol Poisoning

DEER PARK, Ill., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc
(Nasdaq: ETON), a specialty pharmaceutical company focused on developing and
commercializing innovative treatments for rare pediatric diseases, today
announced the U.S. Food and Drug Administration (FDA) has accepted for filing
the company’s new drug application (NDA) for dehydrated alcohol injection. The
application has been assigned a Prescription Drug User Fee Act (PDUFA) date of
May 27, 2021.

Eton’s application previously received orphan drug designation for the
treatment of methanol poisoning and is expected to receive seven years of
market exclusivity upon its approval.

The U.S. market for dehydrated alcohol injection is estimated to be greater
than $100 million annually and the drug is currently only supplied by a single
manufacturer^1.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
developing and commercializing innovative treatments for rare pediatric
diseases. The company currently owns or receives royalties from three
FDA-approved approved products, including ALKINDI® SPRINKLE, Biorphen®, and
Alaway® Preservative Free, and has six additional products in its late-stage
pipeline, including five that have been submitted to the FDA.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with the expected ability of Eton to undertake certain activities
and accomplish certain goals and objectives. These statements include but are
not limited to statements regarding Eton’s business strategy, Eton’s plans to
develop and commercialize its 
Read the rest